Showing 4671-4680 of 7540 results for "".
- Class-Action Suit Against EOS Lip Balm Growshttps://practicaldermatology.com/news/class-action-suit-against-eos-lip-balm-grows/2458750/With their colorful egg-shaped containers, palatable price points ($2.99) and assorted fruity and sweet scents, EOS (which stands for Evolution of Smooth) lip balms have been flying off of store shelves for several years. The lip balms have also bec
- Concern About Zika Virus in US Set to Escalatehttps://practicaldermatology.com/news/concern-about-zika-virus-in-us-set-to-escalate/2458751/U.S dermatologists may start to receive calls from patients who are concerned about infection with Zika virus – particularly pregnant ones. Zika is now spreading rapidly across Latin America and the Caribbean. So far, one case has been identified in Houston, but the possibility
- Study Highlights Risk Factors for cSCC Recurrence, Metastasis and Deathhttps://practicaldermatology.com/news/study-highlights-risk-factors-for-cscc-recurrence-metastasis-and-death/2458753/Tumor depth confers the highest risk of local recurrence and metastasis of cutaneous squamous cell carcinoma (cSCC) and tumor diameter exceeding 20 mm is associated with the highest risk for disease-specific death, a new study suggests. The findings are published online in
- Almirall Exercises Call Option to Acquire ThermiGenhttps://practicaldermatology.com/news/almirall-exercises-call-option-to-acquire-thermigen/2458755/Barcelona pharma company Almirall, S.A., is stepping up their plans to take on ThermiGen LLC. The company is now exercising their call option to acquire 100 percent of the share capital of ThermiGen.
- Ranbaxy Launches Patient Education Resources for Acne Patients Featuring Athlete Kelly Clarkhttps://practicaldermatology.com/news/ranbaxy-launches-patient-education-resources-for-acne-patients-featuring-athlete-kelly-clark/2458758/Ranbaxy Laboratories Inc, a SUN PHARMA company, has launched of a variety of patient education resources featuring gold medal-winning snowboarder and 2015 ESPY Best Female Action Sports Athlete Kelly Clark. The tools are housed on ABSORICA.COM. Absorica<
- Galderma Laboratories, L.P. Appoints Miles Harrison as Leader of U.S. and Canadahttps://practicaldermatology.com/news/galderma-laboratories-lp-appoints-miles-harrison-as-leader-of-us-and-canada/2458762/Galderma promoted Miles Harrison to President and General Manager of Galderma Laboratories, L.P. leading the US and Canada teams. Miles Harrison joined Galderma US in 2014 as the Vice President
- Dermira Completes Patient Enrollment for Third Cimzia Phase 3 Trial in Psoriasis Programhttps://practicaldermatology.com/news/dermira-completes-patient-enrollment-for-third-cimzia-phase-3-trial-in-psoriasis-program/2458760/Dermira, Inc., completed its patient enrollment for the CIMPACT clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. The CIMPACT study is the third and final clinical trial of the CIMZIA Phase 3 development program in moderate-to-s
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- Immune and BioNanoSim Enter Agreement to Develop Novel Topical Nano-Capsule Formulation of Cyclosporinehttps://practicaldermatology.com/news/immune-and-bionanosim-enter-agreement-to-develop-novel-topical-nano-capsule-forumlation-of-cyclosporine/2458768/Immune Pharmaceuticals Inc. entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd. for a novel topical nano-capsule formulation of cyclosporine, also known as cyclosporine-A or CsA. Monica Luchi, M.D., Chief Medical Officer of Immune, commented: "